{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:51:59Z","timestamp":1793742719317,"version":"4.6.1"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41582-024-01023-0","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T15:02:11Z","timestamp":1728313331000},"page":"724-737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9384-1305","authenticated-orcid":false,"given":"Lorraine V.","family":"Kalia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Asis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Arbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7179-0335","authenticated-orcid":false,"given":"Amit","family":"Bar-Or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2034-8800","authenticated-orcid":false,"given":"Riley","family":"Bove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1356-4919","authenticated-orcid":false,"given":"Daniel G.","family":"Di Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5520-6239","authenticated-orcid":false,"given":"Edward A.","family":"Fon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0332-234X","authenticated-orcid":false,"given":"Ziv","family":"Gan-Or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Gommerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Un Jung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Klawiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9972-5092","authenticated-orcid":false,"given":"Marcus","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Kolind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2962-6253","authenticated-orcid":false,"given":"Matthew R.","family":"Lincoln","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny A.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"McKeown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago A.","family":"Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1738-0647","authenticated-orcid":false,"given":"Veronique E.","family":"Miron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ontaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime W. C.","family":"Rousseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Schlossmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1776-2418","authenticated-orcid":false,"given":"Raphael","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9778-7246","authenticated-orcid":false,"given":"A. Jon","family":"Stoessl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5519-6088","authenticated-orcid":false,"given":"Jiwon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"1023_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"GBD 2016 Neurology Collaborators.","year":"2019","unstructured":"GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 459\u2013480 (2019).","journal-title":"Lancet Neurol."},{"key":"1023_CR2","doi-asserted-by":"publisher","first-page":"k4674","DOI":"10.1136\/bmj.k4674","volume":"363","author":"F De Angelis","year":"2018","unstructured":"De Angelis, F., John, N. A. & Brownlee, W. J. Disease-modifying therapies for multiple sclerosis. BMJ 363, k4674 (2018).","journal-title":"BMJ"},{"key":"1023_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav7188","volume":"365","author":"International Multiple Sclerosis Genetics Consortium.","year":"2019","unstructured":"International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 365, eaav7188 (2019).","journal-title":"Science"},{"key":"1023_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41586-023-06250-x","volume":"619","author":"International Multiple Sclerosis Genetics Consortium; MultipleMS Consortium.","year":"2023","unstructured":"International Multiple Sclerosis Genetics Consortium; MultipleMS Consortium. Locus for severity implicates CNS resilience in progression of multiple sclerosis. Nature 619, 323\u2013331 (2023).","journal-title":"Nature"},{"key":"1023_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ajhg.2014.10.004","volume":"95","author":"A Gusev","year":"2014","unstructured":"Gusev, A. et al. Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases. Am. J. Hum. Genet. 95, 535\u2013552 (2014).","journal-title":"Am. J. Hum. Genet."},{"key":"1023_CR6","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1126\/science.1222794","volume":"337","author":"MT Maurano","year":"2012","unstructured":"Maurano, M. T. et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 337, 1190\u20131195 (2012).","journal-title":"Science"},{"key":"1023_CR7","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ng.3795","volume":"49","author":"S Chun","year":"2017","unstructured":"Chun, S. et al. Limited statistical evidence for shared genetic effects of eQTLs and autoimmune-disease-associated loci in three major immune-cell types. Nat. Genet. 49, 600\u2013605 (2017).","journal-title":"Nat. Genet."},{"key":"1023_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf3041","volume":"376","author":"S Yazar","year":"2022","unstructured":"Yazar, S. et al. Single-cell eQTL mapping identifies cell type-specific genetic control of autoimmune disease. Science 376, eabf3041 (2022).","journal-title":"Science"},{"key":"1023_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm2508","volume":"7","author":"BJ Schmiedel","year":"2022","unstructured":"Schmiedel, B. J. et al. Single-cell eQTL analysis of activated T cell subsets reveals activation and cell type-dependent effects of disease-risk variants. Sci. Immunol. 7, eabm2508 (2022).","journal-title":"Sci. Immunol."},{"key":"1023_CR10","doi-asserted-by":"publisher","first-page":"7419","DOI":"10.1073\/pnas.1821778116","volume":"116","author":"JA Hollenbach","year":"2019","unstructured":"Hollenbach, J. A. et al. A specific amino acid motif of HLA-DRB1 mediates risk and interacts with smoking history in Parkinson\u2019s disease. Proc. Natl Acad. Sci. USA 116, 7419\u20137424 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1023_CR11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091\u20131102 (2019).","journal-title":"Lancet Neurol."},{"key":"1023_CR12","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaneurol.2020.0428","volume":"77","author":"JN Foo","year":"2020","unstructured":"Foo, J. N. et al. Identification of risk loci for Parkinson disease in Asians and comparison of risk between Asians and Europeans: a genome-wide association study. JAMA Neurol. 77, 746\u2013754 (2020).","journal-title":"JAMA Neurol."},{"key":"1023_CR13","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/brain\/awad345","volume":"147","author":"E Yu","year":"2023","unstructured":"Yu, E. et al. Machine learning nominates the inositol pathway and novel genes in Parkinson\u2019s disease. Brain 147, 887\u2013899 (2023).","journal-title":"Brain"},{"key":"1023_CR14","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1073\/pnas.1318306111","volume":"111","author":"A Beilina","year":"2014","unstructured":"Beilina, A. et al. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc. Natl Acad. Sci. USA 111, 2626\u20132631 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1023_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/science.abk0637","volume":"377","author":"ME Diaz-Ortiz","year":"2022","unstructured":"Diaz-Ortiz, M. E. et al. GPNMB confers risk for Parkinson\u2019s disease through interaction with \u03b1-synuclein. Science 377, eabk0637 (2022).","journal-title":"Science"},{"key":"1023_CR16","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ana.24497","volume":"78","author":"JM Frischer","year":"2015","unstructured":"Frischer, J. M. et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann. Neurol. 78, 710\u2013721 (2015).","journal-title":"Ann. Neurol."},{"key":"1023_CR17","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1093\/brain\/awh641","volume":"128","author":"A Kutzelnigg","year":"2005","unstructured":"Kutzelnigg, A. et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128, 2705\u20132712 (2005).","journal-title":"Brain"},{"key":"1023_CR18","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1016\/j.cell.2022.08.021","volume":"185","author":"iMSMS Consortium.","year":"2022","unstructured":"iMSMS Consortium. Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course. Cell 185, 3467\u20133486.e16 (2022).","journal-title":"Cell"},{"key":"1023_CR19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41582-022-00681-2","volume":"18","author":"AH Tan","year":"2022","unstructured":"Tan, A. H., Lim, S. Y. & Lang, A. E. The microbiome-gut-brain axis in Parkinson disease \u2014 from basic research to the clinic. Nat. Rev. Neurol. 18, 476\u2013495 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"1023_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg3208","volume":"7","author":"C Yang","year":"2022","unstructured":"Yang, C. et al. Immunoglobulin A antibody composition is sculpted to bind the self gut microbiome. Sci. Immunol. 7, eabg3208 (2022).","journal-title":"Sci. Immunol."},{"key":"1023_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-022-05474-7","volume":"612","author":"J Rustenhoven","year":"2022","unstructured":"Rustenhoven, J. & Kipnis, J. Brain borders at the central stage of neuroimmunology. Nature 612, 417\u2013429 (2022).","journal-title":"Nature"},{"key":"1023_CR22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/s41586-020-2886-4","volume":"587","author":"Z Fitzpatrick","year":"2020","unstructured":"Fitzpatrick, Z. et al. Gut-educated IgA plasma cells defend the meningeal venous sinuses. Nature 587, 472\u2013476 (2020).","journal-title":"Nature"},{"key":"1023_CR23","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1093\/brain\/awr182","volume":"134","author":"OW Howell","year":"2011","unstructured":"Howell, O. W. et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134, 2755\u20132771 (2011).","journal-title":"Brain"},{"key":"1023_CR24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/brain\/awm038","volume":"130","author":"R Magliozzi","year":"2007","unstructured":"Magliozzi, R. et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130, 1089\u20131104 (2007).","journal-title":"Brain"},{"key":"1023_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","volume":"14","author":"B Serafini","year":"2004","unstructured":"Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E. & Aloisi, F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 14, 164\u2013174 (2004).","journal-title":"Brain Pathol."},{"key":"1023_CR26","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.immuni.2015.11.010","volume":"43","author":"NB Pikor","year":"2015","unstructured":"Pikor, N. B. et al. Integration of Th17- and lymphotoxin-derived signals initiates meningeal-resident stromal cell remodeling to propagate neuroinflammation. Immunity 43, 1160\u20131173 (2015).","journal-title":"Immunity"},{"key":"1023_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/ana.23882","volume":"74","author":"M Calabrese","year":"2013","unstructured":"Calabrese, M. et al. The changing clinical course of multiple sclerosis: a matter of gray matter. Ann. Neurol. 74, 76\u201383 (2013).","journal-title":"Ann. Neurol."},{"key":"1023_CR28","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.158144","volume":"7","author":"M Zuo","year":"2022","unstructured":"Zuo, M. et al. Age-dependent gray matter demyelination is associated with leptomeningeal neutrophil accumulation. JCI Insight 7, e158144 (2022).","journal-title":"JCI Insight"},{"key":"1023_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(22)00184-3","volume":"22","author":"JS Graves","year":"2023","unstructured":"Graves, J. S. et al. Ageing and multiple sclerosis. Lancet Neurol. 22, 66\u201377 (2023).","journal-title":"Lancet Neurol."},{"key":"1023_CR30","doi-asserted-by":"publisher","first-page":"1197212","DOI":"10.3389\/fneur.2023.1197212","volume":"14","author":"G Macaron","year":"2023","unstructured":"Macaron, G. et al. Impact of aging on treatment considerations for multiple sclerosis patients. Front. Neurol. 14, 1197212 (2023).","journal-title":"Front. Neurol."},{"key":"1023_CR31","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"TR Sampson","year":"2016","unstructured":"Sampson, T. R. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s disease. Cell 167, 1469\u20131480 (2016).","journal-title":"Cell"},{"key":"1023_CR32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","volume":"20","author":"N Vijiaratnam","year":"2021","unstructured":"Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R. & Foltynie, T. Progress towards therapies for disease modification in Parkinson\u2019s disease. Lancet Neurol. 20, 559\u2013572 (2021).","journal-title":"Lancet Neurol."},{"key":"1023_CR33","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1002\/ana.21489","volume":"64","author":"P Jenner","year":"2008","unstructured":"Jenner, P. Functional models of Parkinson\u2019s disease: a valuable tool in the development of novel therapies. Ann. Neurol. 64, S16\u2013S29 (2008).","journal-title":"Ann. Neurol."},{"key":"1023_CR34","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-0964-2","volume":"566","author":"D Lodygin","year":"2019","unstructured":"Lodygin, D. et al. \u03b2-Synuclein-reactive T cells induce autoimmune CNS grey matter degeneration. Nature 566, 503\u2013508 (2019).","journal-title":"Nature"},{"key":"1023_CR35","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.158153","volume":"7","author":"JR Atkinson","year":"2022","unstructured":"Atkinson, J. R. et al. Biological aging of CNS-resident cells alters the clinical course and immunopathology of autoimmune demyelinating disease. JCI Insight 7, e158153 (2022).","journal-title":"JCI Insight"},{"key":"1023_CR36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-019-1405-y","volume":"571","author":"D Matheoud","year":"2019","unstructured":"Matheoud, D. et al. Intestinal infection triggers Parkinson\u2019s disease-like symptoms in Pink1\u2212\/\u2212 mice. Nature 571, 565\u2013569 (2019).","journal-title":"Nature"},{"key":"1023_CR37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nature14335","volume":"522","author":"FJ Najm","year":"2015","unstructured":"Najm, F. J. et al. Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo. Nature 522, 216\u2013220 (2015).","journal-title":"Nature"},{"key":"1023_CR38","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.devcel.2021.04.006","volume":"56","author":"OG James","year":"2021","unstructured":"James, O. G. et al. iPSC-derived myelinoids to study myelin biology of humans. Dev. Cell 56, 1346\u20131358.e6 (2021).","journal-title":"Dev. Cell"},{"key":"1023_CR39","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/s41592-018-0081-4","volume":"15","author":"M Madhavan","year":"2018","unstructured":"Madhavan, M. et al. Induction of myelinating oligodendrocytes in human cortical spheroids. Nat. Methods 15, 700\u2013706 (2018).","journal-title":"Nat. Methods"},{"key":"1023_CR40","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1212\/01.wnl.0000335764.14513.1a","volume":"72","author":"DT Okuda","year":"2009","unstructured":"Okuda, D. T. et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 72, 800\u2013805 (2009).","journal-title":"Neurology"},{"key":"1023_CR41","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1212\/WNL.0b013e31824528c9","volume":"78","author":"MP Amato","year":"2012","unstructured":"Amato, M. P. et al. Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. Neurology 78, 309\u2013314 (2012).","journal-title":"Neurology"},{"key":"1023_CR42","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/ene.13789","volume":"26","author":"L Bonzano","year":"2019","unstructured":"Bonzano, L. et al. Subclinical motor impairment assessed with an engineered glove correlates with magnetic resonance imaging tissue damage in radiologically isolated syndrome. Eur. J. Neurol. 26, 162\u2013167 (2019).","journal-title":"Eur. J. Neurol."},{"key":"1023_CR43","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jpsychires.2015.05.008","volume":"68","author":"A Labiano-Fontcuberta","year":"2015","unstructured":"Labiano-Fontcuberta, A. et al. Psychiatric disturbances in radiologically isolated syndrome. J. Psychiatr. Res. 68, 309\u2013315 (2015).","journal-title":"J. Psychiatr. Res."},{"key":"1023_CR44","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1177\/13524585211002097","volume":"27","author":"J Oh","year":"2021","unstructured":"Oh, J. et al. Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS. Mult. Scler. 27, 2199\u20132208 (2021).","journal-title":"Mult. Scler."},{"key":"1023_CR45","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000102","volume":"2","author":"CJ Azevedo","year":"2015","unstructured":"Azevedo, C. J. et al. Early CNS neurodegeneration in radiologically isolated syndrome. Neurol. Neuroimmunol. Neuroinflamm. 2, e102 (2015).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1023_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019452","volume":"6","author":"N De Stefano","year":"2011","unstructured":"De Stefano, N. et al. Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis. PLoS ONE 6, e19452 (2011).","journal-title":"PLoS ONE"},{"key":"1023_CR47","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1001\/jamaneurol.2020.0124","volume":"77","author":"S Suthiphosuwan","year":"2020","unstructured":"Suthiphosuwan, S. et al. Paramagnetic rim sign in radiologically isolated syndrome. JAMA Neurol. 77, 653\u2013655 (2020).","journal-title":"JAMA Neurol."},{"key":"1023_CR48","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3174\/ajnr.A6045","volume":"40","author":"S Suthiphosuwan","year":"2019","unstructured":"Suthiphosuwan, S. et al. The central vein sign in radiologically isolated syndrome. Am. J. Neuroradiol. 40, 776\u2013783 (2019).","journal-title":"Am. J. Neuroradiol."},{"key":"1023_CR49","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1523\/JNEUROSCI.2557-14.2015","volume":"35","author":"A Giorgio","year":"2015","unstructured":"Giorgio, A. et al. Appraisal of brain connectivity in radiologically isolated syndrome by modeling imaging measures. J. Neurosci. 35, 550\u2013558 (2015).","journal-title":"J. Neurosci."},{"key":"1023_CR50","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.sleep.2012.10.015","volume":"14","author":"BF Boeve","year":"2013","unstructured":"Boeve, B. F. et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 14, 754\u2013762 (2013).","journal-title":"Sleep Med."},{"key":"1023_CR51","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41531-022-00373-0","volume":"8","author":"GM Riboldi","year":"2022","unstructured":"Riboldi, G. M., Russo, M. J., Pan, L., Watkins, K. & Kang, U. J. Dysautonomia and REM sleep behavior disorder contributions to progression of Parkinson\u2019s disease phenotypes. NPJ Parkinsons Dis. 8, 110 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"1023_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0795-4","volume":"17","author":"J Zhang","year":"2017","unstructured":"Zhang, J., Xu, C. Y. & Liu, J. Meta-analysis on the prevalence of REM sleep behavior disorder symptoms in Parkinson\u2019s disease. BMC Neurol. 17, 23 (2017).","journal-title":"BMC Neurol."},{"key":"1023_CR53","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S1474-4422(18)30162-5","volume":"17","author":"K Knudsen","year":"2018","unstructured":"Knudsen, K. et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 17, 618\u2013628 (2018).","journal-title":"Lancet Neurol."},{"key":"1023_CR54","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.26968","volume":"32","author":"S Lehericy","year":"2017","unstructured":"Lehericy, S. et al. The role of high-field magnetic resonance imaging in parkinsonian disorders: pushing the boundaries forward. Mov. Disord. 32, 510\u2013525 (2017).","journal-title":"Mov. Disord."},{"key":"1023_CR55","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/brain\/awab039","volume":"144","author":"L Zhou","year":"2021","unstructured":"Zhou, L. et al. Increased free water in the substantia nigra in idiopathic REM sleep behaviour disorder. Brain 144, 1488\u20131497 (2021).","journal-title":"Brain"},{"key":"1023_CR56","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/jamaneurol.2017.0985","volume":"74","author":"D Jennings","year":"2017","unstructured":"Jennings, D. et al. Conversion to Parkinson disease in the PARS hyposmic and dopamine transporter-deficit prodromal cohort. JAMA Neurol. 74, 933\u2013940 (2017).","journal-title":"JAMA Neurol."},{"key":"1023_CR57","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ana.25026","volume":"82","author":"A Iranzo","year":"2017","unstructured":"Iranzo, A. et al. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann. Neurol. 82, 419\u2013428 (2017).","journal-title":"Ann. Neurol."},{"key":"1023_CR58","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/mds.26431","volume":"30","author":"D Berg","year":"2015","unstructured":"Berg, D. et al. MDS research criteria for prodromal Parkinson\u2019s disease. Mov. Disord. 30, 1600\u20131611 (2015).","journal-title":"Mov. Disord."},{"key":"1023_CR59","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41531-022-00360-5","volume":"8","author":"J Li","year":"2022","unstructured":"Li, J. et al. Evaluation of the PREDIGT score\u2019s performance in identifying newly diagnosed Parkinson\u2019s patients without motor examination. NPJ Parkinsons Dis. 8, 94 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"1023_CR60","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S1474-4422(15)00178-7","volume":"14","author":"MA Nalls","year":"2015","unstructured":"Nalls, M. A. et al. Diagnosis of Parkinson\u2019s disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol. 14, 1002\u20131009 (2015).","journal-title":"Lancet Neurol."},{"key":"1023_CR61","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/mds.26898","volume":"32","author":"AJ Noyce","year":"2017","unstructured":"Noyce, A. J. et al. PREDICT-PD: an online approach to prospectively identify risk indicators of Parkinson\u2019s disease. Mov. Disord. 32, 219\u2013226 (2017).","journal-title":"Mov. Disord."},{"key":"1023_CR62","doi-asserted-by":"publisher","first-page":"577432","DOI":"10.1016\/j.jneuroim.2020.577432","volume":"350","author":"N Bilge","year":"2020","unstructured":"Bilge, N., Simsek, F., Yevgi, R., Ceylan, M. & Askin, S. Low serum \u03b1-synuclein and oligomer \u03b1-synuclein levels in multiple sclerosis patients. J. Neuroimmunol. 350, 577432 (2020).","journal-title":"J. Neuroimmunol."},{"key":"1023_CR63","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jns.2018.11.003","volume":"396","author":"M Mejia","year":"2019","unstructured":"Mejia, M. et al. Low levels of \u03b1-synuclein in peripheral tissues are related to clinical relapse in relapsing-remitting multiple sclerosis: a pilot cross-sectional study. J. Neurol. Sci. 396, 87\u201393 (2019).","journal-title":"J. Neurol. Sci."},{"key":"1023_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285022","volume":"18","author":"R Razia","year":"2023","unstructured":"Razia, R. et al. Predictive value of \u03b1-synuclein expression in peripheral blood of multiple sclerosis patients: a two-dimensional assessment of a selected biomarker. PLoS ONE 18, e0285022 (2023).","journal-title":"PLoS ONE"},{"key":"1023_CR65","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/jnc.13163","volume":"134","author":"R Antonelou","year":"2015","unstructured":"Antonelou, R. et al. Decreased levels of \u03b1-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis. J. Neurochem. 134, 748\u2013755 (2015).","journal-title":"J. Neurochem."},{"key":"1023_CR66","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1471-4159.2012.07749.x","volume":"122","author":"H Wang","year":"2012","unstructured":"Wang, H. et al. Cerebrospinal fluid \u03b1-synuclein levels are elevated in multiple sclerosis and neuromyelitis optica patients during replase. J. Neurochem. 122, 19\u201323 (2012).","journal-title":"J. Neurochem."},{"key":"1023_CR67","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/NEN.0b013e318196e905","volume":"68","author":"JQ Lu","year":"2009","unstructured":"Lu, J. Q. et al. Association of \u03b1-synuclein immunoreactivity with inflammatory activity in multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 68, 179\u2013189 (2009).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1023_CR68","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.mcn.2006.01.007","volume":"31","author":"D Papadopoulos","year":"2006","unstructured":"Papadopoulos, D., Ewans, L., Pham-Dinh, D., Knott, J. & Reynolds, R. Upregulation of \u03b1-synuclein in neurons and glia in inflammatory demyelinating disease. Mol. Cell. Neurosci. 31, 597\u2013612 (2006).","journal-title":"Mol. Cell. Neurosci."},{"key":"1023_CR69","doi-asserted-by":"publisher","first-page":"578047","DOI":"10.1016\/j.jneuroim.2023.578047","volume":"376","author":"DL Heiden","year":"2023","unstructured":"Heiden, D. L., Monogue, B., Ali, M. D. H. & Beckham, J. D. A functional role for alpha-synuclein in neuroimmune responses. J. Neuroimmunol. 376, 578047 (2023).","journal-title":"J. Neuroimmunol."},{"key":"1023_CR70","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.parkreldis.2018.11.016","volume":"59","author":"LV Kalia","year":"2019","unstructured":"Kalia, L. V. Diagnostic biomarkers for Parkinson\u2019s disease: focus on \u03b1-synuclein in cerebrospinal fluid. Parkinsonism Relat. Disord. 59, 21\u201325 (2019).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1023_CR71","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul, G. et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann. Clin. Transl. Neurol. 3, 812\u2013818 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1023_CR72","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","volume":"6","author":"BR Groveman","year":"2018","unstructured":"Groveman, B. R. et al. Rapid and ultra-sensitive quantitation of disease-associated \u03b1-synuclein seeds in brain and cerebrospinal fluid by \u03b1Syn RT-QuIC. Acta Neuropathol. Commun. 6, 7 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"1023_CR73","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/mds.27646","volume":"34","author":"UJ Kang","year":"2019","unstructured":"Kang, U. J. et al. Comparative study of cerebrospinal fluid \u03b1-synuclein seeding aggregation assays for diagnosis of Parkinson\u2019s disease. Mov. Disord. 34, 536\u2013544 (2019).","journal-title":"Mov. Disord."},{"key":"1023_CR74","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1002\/mds.28611","volume":"36","author":"NK Majbour","year":"2021","unstructured":"Majbour, N. K. et al. Cerebrospinal \u03b1-synuclein oligomers reflect disease motor severity in DeNoPa longitudinal cohort. Mov. Disord. 36, 2048\u20132056 (2021).","journal-title":"Mov. Disord."},{"key":"1023_CR75","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/acn3.51280","volume":"8","author":"CD Orru","year":"2021","unstructured":"Orru, C. D. et al. A rapid \u03b1-synuclein seed assay of Parkinson\u2019s disease CSF panel shows high diagnostic accuracy. Ann. Clin. Transl. Neurol. 8, 374\u2013384 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1023_CR76","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/brain\/awab431","volume":"145","author":"I Poggiolini","year":"2022","unstructured":"Poggiolini, I. et al. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain 145, 584\u2013595 (2022).","journal-title":"Brain"},{"key":"1023_CR77","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi, M. et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. 140, 49\u201362 (2020).","journal-title":"Acta Neuropathol."},{"key":"1023_CR78","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s40478-021-01282-8","volume":"9","author":"MJ Russo","year":"2021","unstructured":"Russo, M. J. et al. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease. Acta Neuropathol. Commun. 9, 179 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"1023_CR79","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407\u2013417 (2023).","journal-title":"Lancet Neurol."},{"key":"1023_CR80","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/ana.25447","volume":"85","author":"A van Rumund","year":"2019","unstructured":"van Rumund, A. et al. \u03b1-Synuclein real-time quaking-induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism. Ann. Neurol. 85, 777\u2013781 (2019).","journal-title":"Ann. Neurol."},{"key":"1023_CR81","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU Hoglinger","year":"2024","unstructured":"Hoglinger, G. U. et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 23, 191\u2013204 (2024).","journal-title":"Lancet Neurol."},{"key":"1023_CR82","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni, T. et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178\u2013190 (2024).","journal-title":"Lancet Neurol."},{"key":"1023_CR83","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ana.26555","volume":"93","author":"DT Okuda","year":"2023","unstructured":"Okuda, D. T. et al. Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome. Ann. Neurol. 93, 604\u2013614 (2023).","journal-title":"Ann. Neurol."},{"key":"1023_CR84","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2023.2815","volume":"80","author":"C Lebrun-Frenay","year":"2023","unstructured":"Lebrun-Frenay, C. et al. Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome: the TERIS randomized clinical trial. JAMA Neurol. 80, 1080\u20131088 (2023).","journal-title":"JAMA Neurol."},{"key":"1023_CR85","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/JPD-202472","volume":"11","author":"TA Mestre","year":"2021","unstructured":"Mestre, T. A. et al. Parkinson\u2019s disease subtypes: critical appraisal and recommendations. J. Parkinsons Dis. 11, 395\u2013404 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"1023_CR86","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1212\/WNL.40.10.1529","volume":"40","author":"J Jankovic","year":"1990","unstructured":"Jankovic, J. et al. Variable expression of Parkinson\u2019s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40, 1529\u20131534 (1990).","journal-title":"Neurology"},{"key":"1023_CR87","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamaneurol.2015.0703","volume":"72","author":"SM Fereshtehnejad","year":"2015","unstructured":"Fereshtehnejad, S. M. et al. New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol. 72, 863\u2013873 (2015).","journal-title":"JAMA Neurol."},{"key":"1023_CR88","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano, G. et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease. Nat. Med. 30, 1096\u20131103 (2024).","journal-title":"Nat. Med."},{"key":"1023_CR89","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/brain\/awx118","volume":"140","author":"SM Fereshtehnejad","year":"2017","unstructured":"Fereshtehnejad, S. M., Zeighami, Y., Dagher, A. & Postuma, R. B. Clinical criteria for subtyping Parkinson\u2019s disease: biomarkers and longitudinal progression. Brain 140, 1959\u20131976 (2017).","journal-title":"Brain"},{"key":"1023_CR90","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.parkreldis.2016.04.027","volume":"28","author":"T Simuni","year":"2016","unstructured":"Simuni, T. et al. How stable are Parkinson\u2019s disease subtypes in de novo patients: analysis of the PPMI cohort? Parkinsonism Relat. Disord. 28, 62\u201367 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1023_CR91","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann, T. et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 22, 78\u201388 (2023).","journal-title":"Lancet Neurol."},{"key":"1023_CR92","doi-asserted-by":"publisher","first-page":"104662","DOI":"10.1016\/j.ebiom.2023.104662","volume":"93","author":"A Bar-Or","year":"2023","unstructured":"Bar-Or, A. et al. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine 93, 104662 (2023).","journal-title":"EBioMedicine"},{"key":"1023_CR93","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1056\/NEJM199301213280305","volume":"328","author":"Parkinson Study Group.","year":"1993","unstructured":"Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson\u2019s disease. N. Engl. J. Med. 328, 176\u2013183 (1993).","journal-title":"N. Engl. J. Med."},{"key":"1023_CR94","unstructured":"Fahn, S., Marsden, C. D., Goldstein, M. & Calne, D. B. in Recent Developments in Parkinson\u2019s Disease Vol. 2 (ed. Fahn, S.) 153\u2013163 (Macmillan Healthcare Information, 1987)."},{"key":"1023_CR95","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/mds.21198","volume":"22","author":"CG Goetz","year":"2007","unstructured":"Goetz, C. G. et al. Movement disorder society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov. Disord. 22, 41\u201347 (2007).","journal-title":"Mov. Disord."},{"key":"1023_CR96","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn, S. et al. Levodopa and the progression of Parkinson\u2019s disease. N. Engl. J. Med. 351, 2498\u20132508 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1023_CR97","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","volume":"361","author":"CW Olanow","year":"2009","unstructured":"Olanow, C. W. et al. A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease. N. Engl. J. Med. 361, 1268\u20131278 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1023_CR98","doi-asserted-by":"publisher","first-page":"e367","DOI":"10.1212\/WNL.0000000000201448","volume":"100","author":"HL Frequin","year":"2023","unstructured":"Frequin, H. L. et al. Levodopa response in patients with early Parkinson disease: further observations of the LEAP study. Neurology 100, e367\u2013e376 (2023).","journal-title":"Neurology"},{"key":"1023_CR99","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444\u20131452 (1983).","journal-title":"Neurology"},{"key":"1023_CR100","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1191\/1352458502ms845oa","volume":"8","author":"RA Rudick","year":"2002","unstructured":"Rudick, R. A., Cutter, G. & Reingold, S. The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials. Mult. Scler. 8, 359\u2013365 (2002).","journal-title":"Mult. Scler."},{"key":"1023_CR101","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.msard.2017.01.007","volume":"12","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni, G. et al. Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Mult. Scler. Relat. Disord. 12, 70\u201378 (2017).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1023_CR102","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","volume":"17","author":"R Kapoor","year":"2018","unstructured":"Kapoor, R. et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 17, 405\u2013415 (2018).","journal-title":"Lancet Neurol."},{"key":"1023_CR103","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/13524585241244751","volume":"30","author":"N Montobbio","year":"2024","unstructured":"Montobbio, N. et al. Therapeutic lag: is treatment effect delayed in progressive MS? Mult. Scler. 30, 843\u2013846 (2024).","journal-title":"Mult. Scler."},{"key":"1023_CR104","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1177\/1352458517690823","volume":"23","author":"RW Motl","year":"2017","unstructured":"Motl, R. W. et al. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Mult. Scler. 23, 704\u2013710 (2017).","journal-title":"Mult. Scler."},{"key":"1023_CR105","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1007\/s00415-022-11171-2","volume":"269","author":"MW Koch","year":"2022","unstructured":"Koch, M. W. et al. The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset. J. Neurol. 269, 5319\u20135327 (2022).","journal-title":"J. Neurol."},{"key":"1023_CR106","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1212\/WNL.0000000000011123","volume":"96","author":"MW Koch","year":"2021","unstructured":"Koch, M. W. et al. Reliability of outcome measures in clinical trials in secondary progressive multiple sclerosis. Neurology 96, e111\u2013e120 (2021).","journal-title":"Neurology"},{"key":"1023_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon, R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 10, 1\u201310 (1989).","journal-title":"Control. Clin. Trials"},{"key":"1023_CR108","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/nrneurol.2015.34","volume":"11","author":"MW Koch","year":"2015","unstructured":"Koch, M. W. et al. The promise of futility trials in neurological diseases. Nat. Rev. Neurol. 11, 300\u2013305 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"1023_CR109","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ana.26239","volume":"90","author":"MW Koch","year":"2021","unstructured":"Koch, M. W. et al. Hydroxychloroquine for primary progressive multiple sclerosis. Ann. Neurol. 90, 940\u2013948 (2021).","journal-title":"Ann. Neurol."},{"key":"1023_CR110","doi-asserted-by":"publisher","first-page":"e2313","DOI":"10.1212\/WNL.0000000000011863","volume":"96","author":"MW Koch","year":"2021","unstructured":"Koch, M. W. et al. Repurposing domperidone in secondary progressive multiple sclerosis: a Simon 2-stage phase 2 futility trial. Neurology 96, e2313\u2013e2322 (2021).","journal-title":"Neurology"},{"key":"1023_CR111","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1212\/01.wnl.0000250355.28474.8e","volume":"68","author":"NINDS NET-PD Investigators.","year":"2007","unstructured":"NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68, 20\u201328 (2007).","journal-title":"Neurology"},{"key":"1023_CR112","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.nicl.2016.02.012","volume":"12","author":"A Rahmim","year":"2016","unstructured":"Rahmim, A. et al. Application of texture analysis to DAT SPECT imaging: relationship to clinical assessments. Neuroimage Clin. 12, e1\u2013e9 (2016).","journal-title":"Neuroimage Clin."},{"key":"1023_CR113","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/mds.27361","volume":"33","author":"T Simuni","year":"2018","unstructured":"Simuni, T. et al. Longitudinal change of clinical and biological measures in early Parkinson\u2019s disease: Parkinson\u2019s Progression Markers Initiative cohort. Mov. Disord. 33, 771\u2013782 (2018).","journal-title":"Mov. Disord."},{"key":"1023_CR114","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/ana.24820","volume":"81","author":"JH Kordower","year":"2017","unstructured":"Kordower, J. H. et al. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann. Neurol. 81, 46\u201357 (2017).","journal-title":"Ann. Neurol."},{"key":"1023_CR115","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.10720","volume":"54","author":"CW Olanow","year":"2003","unstructured":"Olanow, C. W. et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson\u2019s disease. Ann. Neurol. 54, 403\u2013414 (2003).","journal-title":"Ann. Neurol."},{"key":"1023_CR116","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","volume":"287","author":"Parkinson Study Group","year":"2002","unstructured":"Parkinson Study Group Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287, 1653\u20131661 (2002).","journal-title":"JAMA"},{"key":"1023_CR117","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/ana.10609","volume":"54","author":"AL Whone","year":"2003","unstructured":"Whone, A. L. et al. Slower progression of Parkinson\u2019s disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. 54, 93\u2013101 (2003).","journal-title":"Ann. Neurol."},{"key":"1023_CR118","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1002\/mds.29186","volume":"37","author":"K Matsuoka","year":"2022","unstructured":"Matsuoka, K. et al. High-contrast imaging of \u03b1-synuclein pathologies in living patients with multiple system atrophy. Mov. Disord. 37, 2159\u20132161 (2022).","journal-title":"Mov. Disord."},{"key":"1023_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42305-3","volume":"14","author":"R Smith","year":"2023","unstructured":"Smith, R. et al. The \u03b1-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. Nat. Commun. 14, 6750 (2023).","journal-title":"Nat. Commun."},{"key":"1023_CR120","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1016\/j.cell.2023.06.004","volume":"186","author":"J Xiang","year":"2023","unstructured":"Xiang, J. et al. Development of an \u03b1-synuclein positron emission tomography tracer for imaging synucleinopathies. Cell 186, 3350\u20133367.e19 (2023).","journal-title":"Cell"},{"key":"1023_CR121","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/ana.24791","volume":"80","author":"E Herranz","year":"2016","unstructured":"Herranz, E. et al. Neuroinflammatory component of gray matter pathology in multiple sclerosis. Ann. Neurol. 80, 776\u2013790 (2016).","journal-title":"Ann. Neurol."},{"key":"1023_CR122","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162\u2013173 (2018).","journal-title":"Lancet Neurol."},{"key":"1023_CR123","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/jnnp.54.8.683","volume":"54","author":"DH Miller","year":"1991","unstructured":"Miller, D. H. et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J. Neurol. Neurosurg. Psychiatry 54, 683\u2013688 (1991).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1023_CR124","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(13)70103-0","volume":"12","author":"MP Sormani","year":"2013","unstructured":"Sormani, M. P. & Bruzzi, P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol. 12, 669\u2013676 (2013).","journal-title":"Lancet Neurol."},{"key":"1023_CR125","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1177\/13524585231204710","volume":"29","author":"S Nicholson","year":"2023","unstructured":"Nicholson, S. et al. The effect of ibudilast on thalamic volume in progressive multiple sclerosis. Mult. Scler. 29, 1819\u20131830 (2023).","journal-title":"Mult. Scler."},{"key":"1023_CR126","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1002\/mds.25182","volume":"27","author":"G Du","year":"2012","unstructured":"Du, G. et al. Imaging nigral pathology and clinical progression in Parkinson\u2019s disease. Mov. Disord. 27, 1636\u20131643 (2012).","journal-title":"Mov. Disord."},{"key":"1023_CR127","doi-asserted-by":"publisher","first-page":"101597","DOI":"10.1016\/j.nicl.2018.11.007","volume":"21","author":"AR Khan","year":"2019","unstructured":"Khan, A. R. et al. Biomarkers of Parkinson\u2019s disease: striatal sub-regional structural morphometry and diffusion MRI. Neuroimage Clin. 21, 101597 (2019).","journal-title":"Neuroimage Clin."},{"key":"1023_CR128","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/acn3.760","volume":"6","author":"SY Huang","year":"2019","unstructured":"Huang, S. Y. et al. Corpus callosum axon diameter relates to cognitive impairment in multiple sclerosis. Ann. Clin. Transl. Neurol. 6, 882\u2013892 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1023_CR129","doi-asserted-by":"publisher","first-page":"118530","DOI":"10.1016\/j.neuroimage.2021.118530","volume":"243","author":"SY Huang","year":"2021","unstructured":"Huang, S. Y. et al. Connectome 2.0: developing the next-generation ultra-high gradient strength human MRI scanner for bridging studies of the micro-, meso- and macro-connectome. Neuroimage 243, 118530 (2021).","journal-title":"Neuroimage"},{"key":"1023_CR130","doi-asserted-by":"publisher","first-page":"fcad153","DOI":"10.1093\/braincomms\/fcad153","volume":"5","author":"EA Krijnen","year":"2023","unstructured":"Krijnen, E. A. et al. Detection of grey matter microstructural substrates of neurodegeneration in multiple sclerosis. Brain Commun. 5, fcad153 (2023).","journal-title":"Brain Commun."},{"key":"1023_CR131","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fnins.2018.00202","volume":"12","author":"JJ FitzGerald","year":"2018","unstructured":"FitzGerald, J. J., Lu, Z., Jareonsettasin, P. & Antoniades, C. A. Quantifying motor impairment in movement disorders. Front. Neurosci. 12, 202 (2018).","journal-title":"Front. Neurosci."},{"key":"1023_CR132","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S1474-4422(20)30347-1","volume":"19","author":"BAC Cree","year":"2020","unstructured":"Cree, B. A. C. et al. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 19, 988\u2013997 (2020).","journal-title":"Lancet Neurol."},{"key":"1023_CR133","doi-asserted-by":"publisher","DOI":"10.2196\/14863","volume":"21","author":"L Midaglia","year":"2019","unstructured":"Midaglia, L. et al. Adherence and satisfaction of smartphone- and smartwatch-based remote active testing and passive monitoring in people with multiple sclerosis: nonrandomized interventional feasibility study. J. Med. Internet Res. 21, e14863 (2019).","journal-title":"J. Med. Internet Res."},{"key":"1023_CR134","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/brain\/122.5.871","volume":"122","author":"GR Cutter","year":"1999","unstructured":"Cutter, G. R. et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122, 871\u2013882 (1999).","journal-title":"Brain"},{"key":"1023_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-15874-4","volume":"12","author":"F Lipsmeier","year":"2022","unstructured":"Lipsmeier, F. et al. Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson\u2019s disease. Sci. Rep. 12, 12081 (2022).","journal-title":"Sci. Rep."},{"key":"1023_CR136","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano, G. et al. Trial of prasinezumab in early-stage Parkinson\u2019s disease. N. Engl. J. Med. 387, 421\u2013432 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1023_CR137","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/acn3.51236","volume":"8","author":"RB Schneider","year":"2021","unstructured":"Schneider, R. B. et al. Design of a virtual longitudinal observational study in Parkinson\u2019s disease (AT-HOME PD). Ann. Clin. Transl. Neurol. 8, 308\u2013320 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1023_CR138","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000500413","volume":"3","author":"A Coravos","year":"2019","unstructured":"Coravos, A. et al. Digital medicine: a primer on measurement. Digit. Biomark. 3, 31\u201371 (2019).","journal-title":"Digit. Biomark."},{"key":"1023_CR139","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/mds.27671","volume":"34","author":"AJ Espay","year":"2019","unstructured":"Espay, A. J. et al. A roadmap for implementation of patient-centered digital outcome measures in Parkinson\u2019s disease obtained using mobile health technologies. Mov. Disord. 34, 657\u2013663 (2019).","journal-title":"Mov. Disord."},{"key":"1023_CR140","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1136\/jnnp-2021-328365","volume":"93","author":"N Vijiaratnam","year":"2022","unstructured":"Vijiaratnam, N. et al. Combining biomarkers for prognostic modelling of Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 93, 707\u2013715 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1023_CR141","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1093\/brain\/awab241","volume":"144","author":"S Bittner","year":"2021","unstructured":"Bittner, S., Oh, J., Havrdova, E. K., Tintore, M. & Zipp, F. The potential of serum neurofilament as biomarker for multiple sclerosis. Brain 144, 2954\u20132963 (2021).","journal-title":"Brain"},{"key":"1023_CR142","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200052","volume":"10","author":"C Barro","year":"2023","unstructured":"Barro, C. et al. Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 10, e200052 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1023_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton, N. J. et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat. Commun. 12, 3400 (2021).","journal-title":"Nat. Commun."},{"key":"1023_CR144","doi-asserted-by":"publisher","first-page":"102807","DOI":"10.1016\/j.ebiom.2020.102807","volume":"56","author":"S Bittner","year":"2020","unstructured":"Bittner, S. et al. Clinical implications of serum neurofilament in newly diagnosed MS patients: a longitudinal multicentre cohort study. EBioMedicine 56, 102807 (2020).","journal-title":"EBioMedicine"},{"key":"1023_CR145","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awy154","volume":"141","author":"C Barro","year":"2018","unstructured":"Barro, C. et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141, 2382\u20132391 (2018).","journal-title":"Brain"},{"key":"1023_CR146","doi-asserted-by":"publisher","first-page":"e1201","DOI":"10.1212\/WNL.0000000000009097","volume":"94","author":"B Delcoigne","year":"2020","unstructured":"Delcoigne, B. et al. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology 94, e1201\u2013e1212 (2020).","journal-title":"Neurology"},{"key":"1023_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35766-w","volume":"8","author":"YS Lin","year":"2018","unstructured":"Lin, Y. S., Lee, W. J., Wang, S. J. & Fuh, J. L. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci. Rep. 8, 17368 (2018).","journal-title":"Sci. Rep."},{"key":"1023_CR148","doi-asserted-by":"publisher","first-page":"959261","DOI":"10.3389\/fnins.2022.959261","volume":"16","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Dou, K., Xue, L., Li, X. & Xie, A. Neurofilament light as a biomarker for motor decline in Parkinson\u2019s disease. Front. Neurosci. 16, 959261 (2022).","journal-title":"Front. Neurosci."},{"key":"1023_CR149","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.clineuro.2011.11.002","volume":"114","author":"W Su","year":"2012","unstructured":"Su, W., Chen, H. B., Li, S. H. & Wu, D. Y. Correlational study of the serum levels of the glial fibrillary acidic protein and neurofilament proteins in Parkinson\u2019s disease patients. Clin. Neurol. Neurosurg. 114, 372\u2013375 (2012).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"1023_CR150","unstructured":"Food and Drug Administration. FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. US FDA https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical (2014)."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01023-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01023-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01023-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T14:05:41Z","timestamp":1732716341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-01023-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":150,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1023"],"URL":"https:\/\/doi.org\/10.1038\/s41582-024-01023-0","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]},"assertion":[{"value":"9 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.V.K. has received research support from Canadian Institutes of Health Research (CIHR), Cure Parkinson\u2019s, Krembil Foundation, Michael J. Fox Foundation for Parkinson\u2019s Research (MJFF), Natural Sciences and Engineering Research Council of Canada, and Parkinson Canada; consultancy fees from Cure Ventures, Ipsen, Knight Therapeutics, Right Brain Bio, and UCB; and honoraria from Canadian Movement Disorders Society, Critical Path for Parkinson\u2019s, International Parkinson and Movement Disorder Society, and IOS Press. A.B.-O. has received personal fees for advisory board participation and\/or consulting from Abata, Accure, Atara Biotherapeutics, Biogen, Bristol Myers Squibb (BMS)\/Celgene\/Receptos, GlaxoSmithKline, Gossamer, Horizon Therapeutics, Immunic, Janssen\/Actelion, Medimmune, Merck\/EMD Serono, Novartis, Roche\/Genentech, Sangamo, Sanofi-Genzyme, and Viracta; and institutional grant support from Biogen Idec, Roche\/Genentech, Merck\/EMD Serono, and Novartis. R.B. has received research support from Biogen, Eli Lilly, and Roche Genentech, and consulting fees from EMD Serono, Novartis, TG Therapeutics, and Horizon, Jansen. S.F. has received consultancy or speaker fees from Abbvie, Bial, Ipsen, and Lundbeck. U.J.K. holds stock options as a Scientific Advisory Board member for Amprion and has received consultancy fees as a Scientific Advisory Board member for NurrOn and as a member of the data monitoring committee for UCB. E.C.K. has received research funding from Abbvie, Biogen, and Genentech and consulting fees from Banner Life Sciences, EMO Serano, Galen\/Atlantica, Greenwich Biosciences, INmune Bio, Myrobalan Therapeutics, OM 1, and TG Therapeutics. M.K. has received travel support and honoraria for advisory boards from Biogen,\u00a0Roche, Novartis, and EMD Serono. S.K. has received institutional grant support from\u00a0Biogen, Roche, and Sanofi-Genzyme. A.E.L. has acted as an adviser for AbbVie, Alector, Amylyx, Aprinoia, Biogen, BioAdvance, BlueRock, Biovie, BMS, Denali, Janssen, Jazz, Lilly, Novartis, Paladin, Pharma 2B, PsychoGenetics, Retrophin, Roche, Sun Pharma, and UCB; has received honoraria from Sun Pharma, AbbVie, and Sunovion; has received grants from Brain Canada, CIHR, Edmond J Safra Philanthropic Foundation, MJFF, Ontario Brain Institute, Parkinson Foundation, Parkinson Canada, and W. Garfield Weston Foundation; has acted as an expert witness in litigation related to paraquat and Parkinson disease; and has received publishing royalties from Elsevier, Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press. M.J.M. has received travel support and honoraria for advisory boards from Ipsen, Merz, and Abbvie. D.O. has received research support from the National Institutes of Health, National Multiple Sclerosis Society, Patient Centered Outcomes Research Institute, Race to Erase MS Foundation, Genentech, Genzyme, Bristol Myers Squibb, and Novartis and consulting fees from Biogen Idec, Bristol Myers Squibb, Genentech\/Roche, Novartis, Pipeline Therapeutics, and Merck. R.S. has received grants from MS Society of Canada and J.P. Bickell Foundation; consulting fees from Novartis; payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from Biogen Idec, Sanofi-Genzyme, EMD Serono, and Roche; has served on advisory boards for Novartis; and has received support to attend a scientific meeting from EMD Serono. J.O. has received personal compensation for consulting from Biogen Idec, BMS, Eli Lilly, EMD Serono, Novartis, Roche, and Sanofi-Genzyme, and institutional grant support from Biogen Idec and Roche. A.A., N.A., D.G.D.L., E.A.F., K.K.L., Z.G.-O., J.L.G., M.R.L., P.A.M., T.A.M., V.E.M., M.W.C.R., M.G.S. and A.J.S. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}